Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys
- 1 October 2003
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 3 (10-11) , 1477-1481
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effect of anti‐CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrixCytometry Part A, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals of the Rheumatic Diseases, 2002
- B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disordersBiochemical Society Transactions, 2002
- Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeysToxicology, 2002
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytesRheumatology, 2001
- Clinical applications of anti-CD20 antibodiesJournal of Laboratory and Clinical Medicine, 1999
- Rituximab: A New Therapeutic Monoclonal Antibody for Non‐Hodgkin's LymphomaCancer Practice, 1998
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994